Retinal artery embolism
(UMLS:C0423390)
- UMLS ID:
- C0423390
- MeSH ID:
- N/A
Synonym(s)
1.
Retinal artery embolism
2.
Embolic spots in retinal arteries
3.
Embolism of retinal artery
4.
embolism; retinal artery
Associated Drug(s)
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Triamcinolone Acetonide | FAERS: 9 | US FAERS | |
| 2 | Triamcinolone | FAERS: 9 | US FAERS | |
| 3 | Rivaroxaban | FAERS: 4 | US FAERS | |
| 4 | Letrozole | FAERS: 3 | OFFSIDES US FAERS | |
| 5 | Sildenafil Citrate | FAERS: 3 | US FAERS | |
| 6 | Tadalafil | FAERS: 3 | US FAERS | |
| 7 | rofecoxib | FAERS: 3 | OFFSIDES US FAERS | |
| 8 | Fingolimod Hydrochloride | FAERS: 2 | US FAERS | |
| 9 | Fluvastatin | FAERS: 2 | US FAERS | |
| 10 | apixaban | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 11 | Acitretin | FAERS: 1 | US FAERS | |
| 12 | Alendronate | FAERS: 1 | US FAERS | |
| 13 | Avalide | FAERS: 1 | US FAERS | |
| 14 | Dutasteride | FAERS: 1 | US FAERS | |
| 15 | Imatinib Mesylate | FAERS: 1 | US FAERS | |
| 16 | Lenalidomide | FAERS: 1 | US FAERS | |
| 17 | Norgestrel | FAERS: 1 | US FAERS | |
| 18 | PCI 32765 | FAERS: 1 | US FAERS | |
| 19 | Pregabalin | FAERS: 1 | US FAERS | |
| 20 | Raloxifene Hydrochloride | FAERS: 1 | US FAERS | |
| 21 | Risperidone | FAERS: 1 | US FAERS | |
| 22 | Rosiglitazone | FAERS: 1 | US FAERS | |
| 23 | Sodium Tetradecyl Sulfate | FAERS: 1 | US FAERS | |
| 24 | Tamoxifen | FAERS: 1 | US FAERS | |
| 25 | Terbinafine | FAERS: 1 | US FAERS | |
| 26 | Amiodarone | OFFSIDES | ||
| 27 | Calcium Chloride | OFFSIDES | ||
| 28 | Diflunisal | OFFSIDES | ||
| 29 | Ibandronic Acid | OFFSIDES | ||
| 30 | Oxazepam | OFFSIDES | ||
| 31 | Tamoxifen | OFFSIDES | ||
| 32 | isosorbide-5-mononitrate | OFFSIDES |
Powered by :
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120241
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.